Clinical pharmacology of carbapenems in neonates

References

• Jacqz-Aigrain E, Kaguelidou F, van den Anker JN. How to optimize the evaluation and use of antibiotics in neonates. Pediatr Clin North Am. 2012;59:1117–28.
   PubMed Web of Science ®Google Scholar
• Gray JW, Patel M. Management of antibiotic-resistant infection in the newborn. Arch Dis Child Educ Pract Ed. 2011;96:122–7.
   PubMed Web of Science ®Google Scholar
• de Hoog M, Mouton JW, van den Anker JN. New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med. 2005;10:185–94.
   PubMed Web of Science ®Google Scholar
• Young TE, Mangum B. Neofax®, 23rd edn. Montvale, NJ, USA: Thomson Reuters; 2010.
   Google Scholar
• Blumer JL. Pharmacokinetic determinants of carbapenem therapy in neonates and children. Pediatr Infect Dis J. 1996;15:733–7.
   PubMed Web of Science ®Google Scholar
• Smits A, Kulo A, de Hoon JN, Allegaert K. Pharmacokinetics of drugs in neonates: pattern recognition beyond compound specific observations. Curr Pharm Des. 2012;18:3119–46.
   PubMed Web of Science ®Google Scholar
• Vieux R, Hascoet JM, Merdariu D, Fresson J, Guillemin F. Glomerular filtration rate reference values in very preterm infants. Pediatrics 2010;125:e1186–92.
   PubMed Web of Science ®Google Scholar
• Allegaert K, Verbesselt R, Naulaers G, van den Anker JN, Rayyan M, Debeer A, et al.. Developmental pharmacology: neonates are not just small adults. Acta Clin Belg. 2008;63:16–24.
   PubMed Web of Science ®Google Scholar
• Xu G, Broadbelt KG, Haynes RL, Folkerth RD, Borenstein NS, Belliveau RA, et al.. Late development of the GABAergic system in the human cerebral cortex and white matter. J Neuropathol Exp Neurol. 2011;70:841–58.
   PubMed Web of Science ®Google Scholar
• Miller AD, Ball AM, Bookstaver PB, Dornblaser EK, Bennett CL. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy 2011;31:408–23.
   PubMed Web of Science ®Google Scholar
• van den Anker JN, Pokorna P, Kinzig-Schippers M, Martinkova J, de Groot R, Drusano GL, et al.. Meropenem pharmacokinetics in the newborn. Antimicrob Agents Chemother. 2009;53:3871–9.
   PubMed Web of Science ®Google Scholar
• Padari H, Metsvaht T, Kõrgvee LT, Germovsek E, Ilmoja ML, Kipper K, et al.. Short versus long infusion of meropenem in very-low-birth-weight neonates. Antimicrob Agents Chemother. 2012;56:4760–4.
   PubMed Web of Science ®Google Scholar
• van Enk JG, Touw DJ, Lafeber HN. Pharmacokinetics of meropenem in preterm neonates. Ther Drug Monit. 2001;23:198–201.
   PubMed Web of Science ®Google Scholar
• Bradley JS, Sauberan JB, Ambrose PG, Bhavnani SM, Rasmussen MR, Capparelli EV. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. Pediatr Infect Dis J. 2008;27:794–9.
   PubMed Web of Science ®Google Scholar
• Smith PB, Cohen-Wolkowiez M, Castro LM, Poindexter B, Bidegain M, Weitkamp JH, et al.. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J. 2011;30:844–9.
   PubMed Web of Science ®Google Scholar
• Freij BJ, McCracken GH Jr, Olsen KD, Threlkeld N. Pharmacokinetics of imipenem-cilastatin in neonates. Antimicrob Agents Chemother. 1985;27:431–5.
   PubMed Web of Science ®Google Scholar
• Gruber WC, Rench MA, Garcia-Prats JA, Edwards MS, Baker CJ. Single-dose pharmacokinetics of imipenem-cilastatin in neonates. Antimicrob Agents Chemother. 1985;27:511–4.
   PubMed Web of Science ®Google Scholar
• Reed MD, Kliegman RM, Yamashita TS, Myers CM, Blumer JL. Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. Antimicrob Agents Chemother. 1990;34:1172–7.
   PubMed Web of Science ®Google Scholar
• Kimura T, Kokubun H, Nowatari M, Matsuura N, Sunakawa K, Kubo H. Population pharmacokinetics of panipenem in neonates and retrospective evaluation of dosage. J Antimicrob Chemother. 2001;47:51–9.
   PubMed Web of Science ®Google Scholar
• Iwai N, Nakamura H, Miyazu M, Kasai K, Taneda Y. Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates. Jpn J Antibiot. 1989;42:1087–101.
   PubMedGoogle Scholar
• Hashira S, Tajima T, Fujii R. Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates. Jpn J Antibiot. 1989;42:1077–86.
   PubMedGoogle Scholar
• Bégué P, Quinet B, Baron S, Challier P, Fontaine JL, Lasfargues G. Clinical and pharmacokinetic study of imipenem/cilastatin in children and newborn infants. Pathol Biol. (Paris) 1989;37:485–90.
   PubMed Web of Science ®Google Scholar
• Cohen-Wolkowiez M, Poindexter B, Bidegain M, Weitkamp JH, Schelonka RL, Randolph DA, et al.. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis. 2012;55:1495–502.
   PubMed Web of Science ®Google Scholar
• Lutsar I, Trafojer UM, Heath PT, Metsvaht T, Standing J, Esposito S, et al.. Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial. Trials 2011;12:215.
   PubMed Web of Science ®Google Scholar
• Dalgic N, Sancar M, Bayraktar B, Dincer E, Pelit S. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children. Scand J Infect Dis. 2011;43:339–43.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman SM, Kearns GL, Topelberg S, Jacobs RF, Mistry GC, Majumdar A, et al.. Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescents. Pediatr Infect Dis J. 2010;29:1072–6.
   PubMed Web of Science ®Google Scholar
• Blumer JL. Pharmacokinetic determinants of carbapenem therapy in neonates and children. Pediatr Infect Dis J. 1996;15:733–7.
   PubMed Web of Science ®Google Scholar
• De Cock RF, Allegaert K, Schreuder MF, Sherwin CM, de Hoog M, van den Anker JN, et al.. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet. 2012;51:105–17.
   PubMed Web of Science ®Google Scholar
• Walker MC, Lam WM, Manasco KB. Continuous and extended infusions of β-lactam antibiotics in the pediatric population. Ann Pharmacother. 2012;46:1537–46.
   PubMed Web of Science ®Google Scholar